JPMorgan reinstated coverage of Amarin with an Underweight rating and no price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMRN:
- New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
- Amarin announces results from new REDUCE-IT analyses
- Amarin Reports Third Quarter 2023 Financial Results
- Amarin expects cash to support continued operations, including European launch
- Amarin reports Q3 adjusted EPS 0c, consensus (4c)